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Aims: To determine the extent of Fas expression in oesophageal squamous cell carcinomas (ESCCs) from
Chinese patients and to correlate Fas expression with clinicopathological prognostic parameters.
Methods: Clinicopathological data were collected from 58 patients with ESCC who underwent
oesophagectomy and had no prior radiotherapy or chemotherapy. Immunostaining was performed on
the primary tumours. Expression of Fas was correlated with patients’ demographics, tumour characteristics
and stage, R category of surgery, and patients’ survival.
Results: The actuarial survival rates of all patients at two and five years after surgery were 48% and 14%,
respectively. Fas expression was detected in 89.7% of ESCCs. Higher Fas expression recorded on a four
point scale correlated with better tumour differentiation (p , 0.01), but not with other patient or tumour
variables. Importantly, higher Fas expression was associated with better survival (p = 0.0317).
Conclusions: These findings suggest that Fas activated apoptosis is important in the pathogenesis of ESCC.
This molecular pathway may be a potential therapeutic target for ESCC.
F
as is a cell surface receptor and a major regulator of
apoptosis.1 It has been defined as a tumour suppressor
gene. Together with its ligand (FasL), Fas is a key
element in the homeostasis of peripheral lymphocytes and
many other types of cells.2 3 Alterations in expression of Fas
and FasL have been reported in malignant lymphomas4 5 and
other solid tumours, including oesophageal squamous cell
carcinoma (ESCC).6–10
‘‘Fas mediated apoptosis may play a part in the natural
mechanism of cellular turnover in squamous epithelium’’
In the normal oesophagus, Fas is expressed in the
oesophageal epithelium, and the intensity of Fas staining
increases from the basal or lower prickle cell layer to the
upper squamous epithelium, where apoptosis occurs.10
Because squamous epithelial cells also coexpress FasL, Fas
mediated apoptosis may play a part in the natural mechan-
ism of cellular turnover in squamous epithelium.11
Immunohistochemical studies on the expression of the Fas
protein in ESCC have shown that Fas is downregulated in
these tumours.7–10 However, there are no available data on the
expression of Fas in ESCC in the Chinese population. The
prognostic relevance of Fas expression in ESCC is also
unknown. The aims of our present study were to (1)
document Fas expression in ESCC, (2) correlate Fas expres-
sion with clinicopathological variables, and (3) assess its role
as a prognostic factor.
PATIENTS AND METHODS
Fifty eight surgically resected ESCC specimens obtained at
oesophagectomy from January 1996 to December 1998 were
selected from the department of pathology, The University of
Hong Kong, at Queen Mary Hospital, Hong Kong. Clinical
information on patients’ demographics, tumour character-
istics and stage, and patient outcome were derived from a
prospectively collected database. All patients who had
undergone surgical resection during the period but without
prior neoadjuvant chemotherapy or radiotherapy were
included. They were all ethnic Chinese from the local
community. The specimens were processed for routine
histopathology. The tissue blocks were fixed in 10% buffered
formalin and embedded in paraffin wax. ESCCs were divided
into three grades: well differentiated, moderately differen-
tiated, and poorly differentiated according to the World
Health Organisation classification.12 The ESCCs were staged
according to the TNM classification.13 The R category of the
residual tumour was classified according to the UICC system,
where R0 indicates macroscopic and microscopic tumour
clearance, R1 indicates microscopic residual tumour, and R2
indicates macroscopic residual tumour.14
The expression of Fas was examined by immunohisto-
chemistry in the 58 ESCC tumour specimens and correspond-
ing morphologically normal non-tumour oesophageal
mucosal tissues from the proximal resection margin.
Figure 1 The morphologically normal oesophageal epithelium shows a
pronounced decrease in Fas expression from the surface to the prickle
cell layer. The basal and suprabasal prickle cells show almost no Fas
expression.
Abbreviations: ESCC, oesophageal squamous cell carcinoma; FasL,
Fas ligand
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Immunohistochemistry
Paraffin wax embedded sections were cut from one of the
representative tumour blocks and the morphologically
normal mucosal tissue from the proximal resection margin
from each case of ESCC. They were mounted on to
triethoxysilylpropylamine (TESPA; Sigma Chemicals, St
Louis, Missouri, USA) coated glass slides. Sections (4 mm
thick) were dried overnight in a 42 C˚ incubator and then
used immediately or kept at room temperature for later use.
They were dewaxed in xylene and then hydrated in graded
alcohol.
Immunostaining was performed using the three step Dako
LSAB+ horseradish peroxidase system (K0690; Dako,
Glostrup, Denmark) and the Fas C-20 (SC-715) primary
antibody, which is specific for Fas of human origin (Santa
Cruz Biotechnology Inc, Santa Cruz, California, USA). Fas C-
20 is a rabbit polyclonal IgG antibody that recognises an
epitope mapping to the C-terminus of human Fas. A dilution
of 1/600 (0.33 mg/ml) gave optimal results.
Antigen retrieval or unmasking by microwave pretreat-
ment was performed according to the manufacturer’s (Dako)
recommendations. After dewaxing and hydration, all paraffin
wax embedded sections were placed in plastic microwave
penetrable jars containing 10mM citrate buffer at pH 6.0, and
heated in a microwave oven (H2800; Energy Beam Sciences,
Agawam, Massachusetts, USA) at 95 C˚ for 10 minutes. All
tissue sections were blocked with 0.1% avidin followed by
0.1% biotin for 10 minutes each using the Biotin Blocking kit
(X0590; Dako), then treated with 3% hydrogen peroxide for
30 minutes. Before the application of the primary antibody,
sections were further blocked at room temperature for 30
minutes with 10–20% non-immune serum derived from the
same species of animal as the secondary antibody. The
sections were incubated with Fas C-20 primary antibody at
the predetermined optimal dilution of 1/600 for one hour. The
slides were then incubated at 37 C˚ for 20 minutes with
biotinylated secondary antibody solution from the kit. This
was followed by three washes with phosphate buffered
saline. Afterwards, the signal was amplified by incubation
with the streptavidin–enzyme conjugate at 37 C˚ for 20
minutes, followed by three washes with phosphate buffered
saline. The signals were visualised under the microscope after
incubating with the substrate chromogen solution (3,39-
diaminobenzidine) at room temperature for not more than
two minutes. The reaction was stopped when signals on the
morphological normal epithelium or lymphocytes could be
seen under the microscope. After visualisation, the tissue
sections were counterstained to highlight the nuclei with
Lillian and Mayer’s haematoxylin.
Cells showing granular brown staining were considered
positive and expression was assessed on a four point system
based on the proportion of positive cells as follows: 2, , 5%
of cells positive; +, 5–10% cells positive; ++ 10–20% cells
positive; and +++, . 20% cells positive.
Statistical analyses
Comparisons between groups were performed using the
ANOVA test or Kruskal-Wallis H test for continuous
variables, and Fisher’s exact test or Kendall’s t – b test for
categorical variables where appropriate. Survival curves were
analysed using the Kaplan–Meier method and comparison
between groups was performed using the log rank test.
Multivariate analysis for survival was performed using the
Cox proportional hazard model. A p value of less than 0.05
was regarded as significant. Statistical analysis was per-
formed using SPSS package version 11.0 for windows (SPSS
Inc, Chicago, Illinois, USA).
RESULTS
Fas expression in the non-tumorous, morphologically normal
oesophageal epithelium was higher in differentiated cell
layers such as the superficial layer and the upper part of the
prickle cell layer. It gradually decreased and was negative in
the basal cell layer (fig 1).
Fas was expressed by the ESCC tumour cells in 52 of the 58
cases (fig 2). It was notable that the ESCC tumour cells at the
periphery of the tumour islands were frequently Fas negative,
whereas the centrally located tumour cells expressed Fas
strongly. In six cases, the tumour cells were Fas negative,
whereas the normal epithelium and infiltrating lymphocytes
were positive.
Figure 2 Fas expression in
oesophageal squamous cell carcinoma
showing (A) negative (2), (B) +, (C) ++,
and (D) Fas +++ immunostaining.
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Table 1 shows Fas expression in relation to various
clinicopathological parameters. Using the four point scale,
tumour differentiation was highly correlated with Fas
expression (p , 0.01). However, there was no association
between Fas expression and patients’ demographics, size and
location of the tumour, TNM stage, and R category of
resection.
Figure 3 shows the patients’ survival in relation to Fas
expression. Patients with no expression or weakly (2 or +)
expressed Fas had significantly worse median survival (11.8
months) than those with moderately or strongly (++ or +++)
expressed Fas (28.2 months) (p = 0.0317). Multivariate
analysis for prognostic factors was carried out by means of
Cox proportional hazard analysis using the following vari-
ables: age, sex, tumour differentiation, T stage, N stage,
overall TNM stage, R category of resection, and Fas
expression (M stage was excluded because of colinearity
with other TNM parameters). Using a forward selection
algorithm with likelihood ratio criteria, Fas expression and
overall TNM stage were independent prognostic factors. High
Fas expression correlated with better survival (hazard ratio,
0.639; 95% confidence interval, 0.442 to 0.925), whereas
advanced disease stage was associated with poor survival
(hazard ratio, 2.635; 95% confidence interval, 1.378 to 5.038).
DISCUSSION
Despite recent advances in the treatment of ESCC,15 16 this
disease remains a highly lethal malignancy, mainly because
presentation is at a late disease stage when the tumour is
often not amenable to surgical resection. The two and five
year actuarial survival rates of patients in our current study
were 48% and 14%, respectively. New approaches to the
treatment of ESCC, such as neoadjuvant chemotherapy or
chemoradiotherapy, have no definite benefits over surgical
resection alone.15 16
Immunostaining for Fas in normal oesophageal epithelium
was consistent with the results of a previous study.11 Because
squamous epithelial cells also coexpress FasL, Fas mediated
apoptosis probably plays a part in the natural turnover of the
squamous epithelium. Recently, polymorphisms of the Fas
and FasL genes have been implicated in the pathogenesis of
ESCC in Chinese.17
Table 1 Correlation between clinicopathological features and Fas expression
Feature Total Fas 2 Fas + Fas ++ Fas +++ p Value
Mean (SD) age (years) 63.5 (9.4) 57.7 (11.8) 70.7 (6.0) 63.3 (9.9) 63.0 (8.0) 0.08
Sex (M/F) 48/10 5:1 5:2 20:4 18:3 0.90
Differentiation
Well 18 0 0 5 13 ,0.01
Moderately 24 1 3 15 5
Poorly 16 5 4 4 3
T stage
T1 2 0 1 0 1 0.46
T2 3 0 0 1 2
T3 37 5 6 15 11
T4 16 1 0 8 7
N stage
N0 23 4 3 7 9 0.37
N1 35 2 4 17 12
M stage
M0 55 6 7 22 20 1.00
M1 3 0 0 2 1
Stage
I 1 0 0 0 1 0.45
II 18 4 4 3 7
III 36 2 3 19 12
IV 3 0 0 2 1
Location
Cervical 5 1 1 3 0 0.83
Upper 5 1 0 2 2
Middle 32 3 5 11 13
Lower 14 1 1 7 5
Double primary 2 0 0 1 1
R category
R0 41 5 6 16 14 0.77
R1/R2 17 1 1 8 7
Tumour size (cm)
Median 5.5 6.0 4.5 5.45 6.0 0.49
Minimum 2.0 3.5 3.0 2.0 3.0
Maximum 11 9.5 8.0 10.5 11.0
100
80
60
40
20
0
6
Years
–/+ (n = 13) 
%
0 54321
++/+++ (n = 45) 
Figure 3 Correlation of Fas expression in oesophageal squamous cell
carcinoma with patients’ survival. Patients with no or weak Fas
expression (2 or +) had a median survival of 11.8 months and those
with moderate or strong Fas expression (++ or +++) had a median
survival of 28.2 months (p = 0.0317).
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However, the results of immunostaining for Fas in ESCC
using a four point scale did not correlate with the
clinicopathological parameters examined, except for tumour
differentiation. Keratinisation is the hallmark of well
differentiated ESCC, and keratinising cells of ESCC have
been found to be more apoptotic.18 As shown here, tumour
cells in well differentiated ESCC had higher Fas expression,
similar to that of normal epithelium. It appears that Fas
mediated apoptosis is often retained despite the malignant
transformation process.
‘‘Our findings suggest that Fas activated apoptosis limits
the growth of oesophageal squamous cell carcinoma’’
Fas activated cytotoxic T cells are present in ESCC.19 These
activated T cells express FasL,20 21 which could trigger the Fas
mediated apoptotic pathway of the tumour cells if the Fas
system were intact. We found that the ESCC tumour cells at
the periphery of the tumour islands were frequently negative
for Fas. Presumably, any Fas expressing tumour cells at the
periphery of tumour islands would be eliminated by Fas
activated cytotoxic T cells migrating from the stroma. In this
way, the access of cytotoxic cells to tumour cells most
susceptible to attack could be physically prevented by the less
susceptible ones, thus maintaining a higher proportion of Fas
expressing cells than would otherwise be present. This could
also explain why higher Fas expression in ESCC correlated
with better survival. Further studies should be carried out to
correlate prognosis with Fas expression in ESCC, the degree
of cytotoxic T cell infiltration, and FasL expression in these T
cells.
In summary, our study showed that better tumour
differentiation correlated with higher Fas expression. More
importantly, higher Fas expression was associated with
longer survival of patients. These findings suggest that Fas
activated apoptosis limits the growth of ESCC, although
further work is necessary to establish whether this molecular
pathway is indeed functional and could be exploited for
therapeutic advantages.
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Take home messages
N In oesophageal squamous cell carcinoma (ESCC) Fas
expression significantly correlated with better tumour
differentiation, but not with other patient or tumour
variables
N Higher Fas expression was significantly associated with
better survival
N These findings suggest that Fas activated apoptosis is
important in the pathogenesis of ESCC, and that the
Fas mediated apoptotic pathway may be a potential
therapeutic target in ESCC
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